Moderna (MRNA) Earnings Date & Reports

Key Takeaways

• Revenue beat: Moderna reported Q2 2026 revenue of $145 million, exceeding FactSet consensus of $102.9 million and landing above the company's own guidance range.
• Loss per share improved: GAAP loss per share came in at $1.97, narrower than the $2.13 loss in the same quarter last year and roughly in line with analyst forecasts.
• Cost discipline on display: Operating expenses fell across all categories — cost of sales dropped 22%, R&D declined 7%, and SG&A decreased 6% year-over-year.
• Cash burn remains significant: Cash and investments declined to $6.9 billion from $7.5 billion at the end of Q1, with an additional $950 million litigation settlement paid in July.
• Pipeline catalysts approaching: A pivotal FDA decision on the company's flu vaccine candidate mFLUSIVA is due by August 5, while Phase 3 melanoma data for intismeran is expected in the second half of 2026.
• Full-year guidance improved: Management lowered its 2026 operating expense outlook by roughly $200 million and raised its year-end cash projection to a range of $4.7 billion to $5.2 billion.

Earnings Context and Why It Matters

Moderna's Q2 2026 results landed at a critical moment for the biotechnology company. Since the peak of COVID-19 vaccine demand, the company has been navigating a difficult transition, working to build a diversified portfolio of messenger RNA (mRNA)-based vaccines and therapeutics while simultaneously slashing operating costs. With COVID vaccine sales now highly seasonal and shrinking year-over-year, investors are closely watching whether Moderna can successfully pivot toward new revenue streams — including a seasonal flu vaccine, a personalized cancer treatment, and rare disease therapies. This earnings report provided a snapshot of how management's cost-cutting plan is progressing and offered important updates on near-term pipeline milestones that could reshape the company's growth trajectory.

Reported Results

Moderna reported total revenue of $145 million for the second quarter of 2026, a 2% increase from $142 million in the prior-year period and comfortably above the FactSet consensus estimate of $102.9 million. The top-line result also exceeded the company's previously issued guidance range of $50 million to $100 million. Lower COVID-19 vaccine sales in the U.S. and South America were offset by deliveries to the United Kingdom under a long-term strategic government partnership and higher stand-ready manufacturing and collaboration revenue.

On the bottom line, Moderna posted a GAAP net loss of $782 million, an improvement of $43 million, or 5%, compared to the $825 million loss recorded in Q2 2025. Loss per share (EPS) narrowed to $1.97 from $2.13 a year earlier. Operating expenses declined across all major categories: cost of sales fell 22% to $93 million, research and development (R&D) expenses decreased 7% to $651 million, and selling, general, and administrative (SG&A) expenses dropped 6% to $216 million. The reductions reflected lower unutilized manufacturing capacity costs, the wind-down of several late-stage clinical programs, and continued organizational cost discipline.

Cash, cash equivalents, and investments stood at $6.9 billion as of June 30, 2026, down from $7.5 billion at the end of the first quarter. The company subsequently paid $950 million in July related to the litigation settlement announced earlier in the year.

AI Screener

For investors looking to identify opportunities across the biotechnology and pharmaceutical sectors, Tickeron's AI Screener offers a powerful way to filter the market using AI-driven signals. The AI Screener is an intelligent stock and ETF discovery tool that allows traders and investors to scan thousands of securities based on customizable criteria such as industry classification, market capitalization, technical indicators, price patterns, volatility metrics, and proprietary AI-generated ratings. Whether tracking earnings-season movers, scanning for breakout candidates, or monitoring fundamental shifts across specific sectors, the screener helps users surface trade ideas and market opportunities more efficiently than traditional manual research. Explore the AI Screener to see how data-driven filtering can support your market analysis.

Market Reaction and Investor Sentiment

Moderna shares rose approximately 2% in premarket trading to $59.08 following the earnings release, suggesting that investors were encouraged by the revenue beat and the improved cost outlook. The relatively muted but positive reaction reflected a market that had largely priced in weak COVID vaccine sales and was instead focused on signals of financial discipline and pipeline execution. Heading into the report, analyst sentiment had been cautious — the consensus rating was a "Hold" with an average price target around $49, implying modest downside from pre-earnings levels. The revenue beat and improved full-year expense guidance appeared to offer some reassurance that management's turnaround plan is gaining traction, though significant uncertainty remains around the timing and commercial success of key pipeline programs.

Forward Outlook and Key Factors to Monitor

Looking ahead, Moderna enters the second half of 2026 with several high-stakes catalysts that could meaningfully influence the stock's trajectory. The most immediate event is the August 5 Prescription Drug User Fee Act (PDUFA) date for mFLUSIVA, the company's seasonal influenza vaccine candidate. If approved, it would become Moderna's fifth commercial product and mark a key step in building a seasonal vaccine franchise beyond COVID-19.

Investors are also closely watching the Phase 3 INTerpath-001 trial of intismeran (mRNA-4157), an individualized neoantigen therapy being studied in combination with Merck's Keytruda for high-risk melanoma. Data from this trial are expected in the second half of 2026 and represent what many analysts consider the most significant potential value driver in Moderna's pipeline. A statistically significant result could validate the company's broader oncology ambitions.

On the financial front, management reiterated its target of up to 10% revenue growth for the full year and improved its operating expense outlook by roughly $200 million. Year-end cash is now projected between $4.7 billion and $5.2 billion, providing a runway that extends well beyond 2026. However, the norovirus vaccine candidate mRNA-1403 did not meet statistical criteria for early success at its Phase 3 interim analysis, and the company is preparing to enroll an additional cohort — a reminder that pipeline execution remains inherently uncertain. Investors should continue to monitor expense trends, cash burn rates, and regulatory decisions as the company navigates its post-COVID transformation.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations